Good buy.._老虎社区_美港股上老虎

stormlee
2022-01-21

Good buy..................................

3 Reasons to Buy Teladoc in 2022

Teladoc has what it takes to deliver gains over the long term.

3 Reasons to Buy Teladoc in 2022

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":630810160,"tweetId":"630810160","gmtCreate":1642769465907,"gmtModify":1642770332130,"author":{"id":3571959390768435,"authorId":3571959390768435,"authorIdStr":"3571959390768435","name":"stormlee","avatar":"https://static.tigerbbs.com/80629ef9648273c0d6465aee66dbd98a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":131,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Good buy..................................&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Good buy..................................&nbsp;</p></body></html>","text":"Good buy..................................","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/630810160","repostId":2205460580,"repostType":4,"repost":{"id":"2205460580","pubTimestamp":1642768382,"share":"https://www.laohu8.com/m/news/2205460580?lang=&edition=full","pubTime":"2022-01-21 20:33","market":"us","language":"en","title":"3 Reasons to Buy Teladoc in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2205460580","media":"Motley Fool","summary":"Teladoc has what it takes to deliver gains over the long term.","content":"<html><head></head><body><p>The idea of buying <b>Teladoc Health</b> (NYSE:TDOC) in 2022 may make some investors nervous because the telemedicine stock sank 54% last year. And performance this year isn&#39;t off to a brilliant start, either. The shares have lost about 14% since Dec. 31.</p><p>Investors are worrying that patients may abandon telemedicine after the pandemic ends. And that would mean Teladoc&#39;s best days are behind it. If that&#39;s the case, how will the still-unprofitable company make it to profitability?</p><p>These are risks. But I also see some clues indicating these risks may not take shape. In fact, there are three great reasons to buy shares of Teladoc right now.</p><p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F661990%2Fgettyimages-1288151107.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><h2>1. It&#39;s more than just a COVID stock</h2><p>Some investors viewed Teladoc as a &#34;coronavirus stock&#34; because patients flocked to online medical appointments -- instead of in-person ones -- during the early days of the health crisis. And those investors were right. The pandemic gave Teladoc the opportunity to attract more users and show its strengths. But this doesn&#39;t mean Teladoc won&#39;t perform well post-pandemic.</p><p>We actually have some elements that indicate Teladoc&#39;s business will continue growing in a post-pandemic environment. First, the company has continued to report increasing revenue and medical visits -- well after medical offices returned to normal operations and welcomed patients on site. For example, online visits climbed 37% in the third quarter of last year. And today, 82% of patients consider virtual visits the same as or better than an in-person visit, Teladoc said in a presentation, citing research reports.</p><p>The outlook for the entire telehealth industry also supports the idea that Teladoc&#39;s business gains are far from over. The global market, at a compound annual growth rate of more than 25%, is expected to reach $431 billion by 2030, according to Allied Market Research.</p><p>Teladoc may grow even faster. It predicts a compound annual growth rate of 25% to 30% to reach $4 billion in revenue in 2024. The company estimates there are 298 million total insured lives in the U.S., and 92 million have access to a Teladoc product. This leaves plenty of room for growth over the long term.</p><h2>2. An acquisition that could pay off</h2><p>Teladoc acquired Livongo in 2020. The company is a specialist in the virtual management of chronic conditions like hypertension and diabetes.</p><p>The operation comes with its costs. Various expenses associated with the Livongo acquisition have weighed on earnings. But I see this as a near-term obstacle on the route to profitability.</p><p>The acquisition of Livongo allowed Teladoc to make gains in its quest to serve all of its patients&#39; healthcare needs. We&#39;re already starting to see some results.</p><p>In the third quarter, 24% of Teladoc&#39;s chronic-care members were enrolled in multiple programs. That&#39;s up from 8% in the year-earlier period. And the number of members enrolled in chronic-care programs climbed 31% to 725,000.</p><p>Today, about 6 out of 10 American adults suffer from a chronic disease, according to the Centers for Disease Control and Prevention. This clearly is a population that could represent increases in membership and revenue for Teladoc.</p><h2>3. Valuation</h2><p>As I mentioned earlier, Teladoc&#39;s share performance over the past year looks pretty grim. The stock now is trading at only about six times sales. That&#39;s compared to nearly 25 times sales a year ago.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7e95ac4330890496e2bb2ad574d887ed\" tg-width=\"720\" tg-height=\"433\" width=\"100%\" height=\"auto\"/><span>TDOC PS Ratio data by YCharts.</span></p><p>Wall Street also considers Teladoc cheap at today&#39;s level. It&#39;s trading about $10 below the very lowest 12-month price estimate. And the average Wall Street estimate calls for an 88% gain in the coming year.</p><p>So right now is a good moment to get in on this stock from a valuation perspective -- and from a business perspective. Although Teladoc&#39;s growth and stock performance soared during the early days of the pandemic, that doesn&#39;t mean the Teladoc story is over. In fact, a lot more may lie ahead for this innovative company.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Reasons to Buy Teladoc in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Reasons to Buy Teladoc in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-21 20:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/21/3-reasons-to-buy-teladoc-in-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The idea of buying Teladoc Health (NYSE:TDOC) in 2022 may make some investors nervous because the telemedicine stock sank 54% last year. And performance this year isn't off to a brilliant start, ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/21/3-reasons-to-buy-teladoc-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4567":"ESG概念","BK4534":"瑞士信贷持仓","TDOC":"Teladoc Health Inc.","BK4504":"桥水持仓","BK4548":"巴美列捷福持仓","BK4167":"医疗保健技术"},"source_url":"https://www.fool.com/investing/2022/01/21/3-reasons-to-buy-teladoc-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2205460580","content_text":"The idea of buying Teladoc Health (NYSE:TDOC) in 2022 may make some investors nervous because the telemedicine stock sank 54% last year. And performance this year isn't off to a brilliant start, either. The shares have lost about 14% since Dec. 31.Investors are worrying that patients may abandon telemedicine after the pandemic ends. And that would mean Teladoc's best days are behind it. If that's the case, how will the still-unprofitable company make it to profitability?These are risks. But I also see some clues indicating these risks may not take shape. In fact, there are three great reasons to buy shares of Teladoc right now.Image source: Getty Images.1. It's more than just a COVID stockSome investors viewed Teladoc as a \"coronavirus stock\" because patients flocked to online medical appointments -- instead of in-person ones -- during the early days of the health crisis. And those investors were right. The pandemic gave Teladoc the opportunity to attract more users and show its strengths. But this doesn't mean Teladoc won't perform well post-pandemic.We actually have some elements that indicate Teladoc's business will continue growing in a post-pandemic environment. First, the company has continued to report increasing revenue and medical visits -- well after medical offices returned to normal operations and welcomed patients on site. For example, online visits climbed 37% in the third quarter of last year. And today, 82% of patients consider virtual visits the same as or better than an in-person visit, Teladoc said in a presentation, citing research reports.The outlook for the entire telehealth industry also supports the idea that Teladoc's business gains are far from over. The global market, at a compound annual growth rate of more than 25%, is expected to reach $431 billion by 2030, according to Allied Market Research.Teladoc may grow even faster. It predicts a compound annual growth rate of 25% to 30% to reach $4 billion in revenue in 2024. The company estimates there are 298 million total insured lives in the U.S., and 92 million have access to a Teladoc product. This leaves plenty of room for growth over the long term.2. An acquisition that could pay offTeladoc acquired Livongo in 2020. The company is a specialist in the virtual management of chronic conditions like hypertension and diabetes.The operation comes with its costs. Various expenses associated with the Livongo acquisition have weighed on earnings. But I see this as a near-term obstacle on the route to profitability.The acquisition of Livongo allowed Teladoc to make gains in its quest to serve all of its patients' healthcare needs. We're already starting to see some results.In the third quarter, 24% of Teladoc's chronic-care members were enrolled in multiple programs. That's up from 8% in the year-earlier period. And the number of members enrolled in chronic-care programs climbed 31% to 725,000.Today, about 6 out of 10 American adults suffer from a chronic disease, according to the Centers for Disease Control and Prevention. This clearly is a population that could represent increases in membership and revenue for Teladoc.3. ValuationAs I mentioned earlier, Teladoc's share performance over the past year looks pretty grim. The stock now is trading at only about six times sales. That's compared to nearly 25 times sales a year ago.TDOC PS Ratio data by YCharts.Wall Street also considers Teladoc cheap at today's level. It's trading about $10 below the very lowest 12-month price estimate. And the average Wall Street estimate calls for an 88% gain in the coming year.So right now is a good moment to get in on this stock from a valuation perspective -- and from a business perspective. Although Teladoc's growth and stock performance soared during the early days of the pandemic, that doesn't mean the Teladoc story is over. In fact, a lot more may lie ahead for this innovative company.","news_type":1},"isVote":1,"tweetType":1,"viewCount":571,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":41,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}